{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:33:20Z","timestamp":1770748400051,"version":"3.50.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"am","delay-in-days":651,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejmech.2022.114578","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T11:21:59Z","timestamp":1657365719000},"page":"114578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules"],"prefix":"10.1016","volume":"240","author":[{"given":"Nassima","family":"Oumata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuou","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Cav\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Galons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard P.","family":"Roques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10043","key":"10.1016\/j.ejmech.2022.114578_bib1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114578_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nrl.2016.02.016","article-title":"Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis","volume":"32","author":"Niu","year":"2017","journal-title":"Neurologia"},{"key":"10.1016\/j.ejmech.2022.114578_bib4","article-title":"The identification of PSEN1 p.Tyr159 Ser mutation in a non-canonic early-onset Alzheimer's disease family","volume":"2","author":"Li","year":"2022","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114578_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01518-6","article-title":"A\u03b2 profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset","author":"Petit","year":"2022","journal-title":"Mol. Psychiatr."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114578_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237122","article-title":"The protective mutation A673T in amyloid precursor protein gene decreases A\u03b2 peptides production for 14 forms of Familial Alzheimer's Disease in SH-SY5Y cells","volume":"15","author":"Guyon","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114578_bib7","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jnc.15212","article-title":"Alzheimer's protection effect of A673T mutation may be driven by lower A\u03b2 oligomer binding affinity","volume":"157","author":"Limegrover","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2022.114578_bib8","article-title":"Age-dependent formation of TMEM106B amyloid filaments in human brains","volume":"28","author":"Schweighauser","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","article-title":"Apolipoprotein E and Alzheimer's disease","volume":"12","author":"Troutwine","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114578_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01436-7","article-title":"Alzheimer's Disease Neuroimaging Initiative; ALFA study. Age, sex and APOE-\u03b54 modify the balance between soluble and fibrillar \u03b2-amyloid in non-demented individuals: topographical patterns across two independent cohorts","author":"Cacciaglia","year":"2022","journal-title":"Mol. Psychiatr."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41398-022-01899-w","article-title":"APOE-\u03b54 modulates the association among plasma A\u03b242\/A\u03b240, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults","volume":"12","author":"Shi","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejmech.2022.114578_bib12","article-title":"The Humanistic and economic burden of Alzheimer's disease","volume":"22","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib13","article-title":"Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials","volume":"8","author":"Yu","year":"2022","journal-title":"Alzheimers Dement (N Y)."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114578_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40520-019-01359-4","article-title":"Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders","volume":"33","author":"Benfante","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2022","key":"10.1016\/j.ejmech.2022.114578_bib16","article-title":"Aducanumab therapy to treat Alzheimer's disease: a narrative review","volume":"9","author":"Beshir","year":"2022","journal-title":"Int. J. Alzheimer's Dis."},{"key":"10.1016\/j.ejmech.2022.114578_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112746","article-title":"Aducanumab\" making a comeback in Alzheimer's disease: an old wine in a new bottle","volume":"148","author":"Behl","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114578_bib18","first-page":"1","article-title":"End-of-Life Care in Dementia Research Group. Which has more influence on a family's assessment of the quality of dying of their long-term care resident with dementia: frequency of symptoms or quality of communication with healthcare team?","volume":"29","author":"Charest-Drapeau","year":"2022","journal-title":"Palliat. Support Care"},{"key":"10.1016\/j.ejmech.2022.114578_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2020.102248","article-title":"Select Atrophied Regions in Alzheimer disease (SARA): an improved volumetric model for identifying Alzheimer disease dementia","volume":"26","author":"Koenig","year":"2020","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.ejmech.2022.114578_bib20","article-title":"Predicting symptom onset in sporadic Alzheimer's disease: \"How long do I have?","volume":"21","author":"Schindler","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.ejmech.2022.114578_bib21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimer's Dementia"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","article-title":"Tau aggregation and its interplay with amyloid-\u03b2","volume":"129","author":"Nisbet","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/cells11050919","article-title":"Waste clearance in the brain and neuroinflammation: a novel perspective on biomarker and drug target discovery in Alzheimer's disease","volume":"11","author":"Uchida","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2022.114578_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer's disease: the path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Holtzman","year":"2019","journal-title":"Cell"},{"issue":"5054","key":"10.1016\/j.ejmech.2022.114578_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/1565","article-title":"Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau","volume":"1","author":"Hardy","year":"1998","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114578_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114578_bib29","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114578_bib30","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"17","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114578_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108122","article-title":"Physiology and pharmacology of amyloid precursor protein","volume":"235","author":"Cho","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114578_bib32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1039\/D1SC02990H","article-title":"Amyloid-\u03b2 peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-\u03b2 42 aggregation","volume":"13","author":"Braun","year":"2022","journal-title":"Chem. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114578_bib33","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/ijms23042011","article-title":"Aducanumab and its effects on tau pathology: is this the turning point of amyloid hypothesis?","volume":"23","author":"Silvestro","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114578_bib34","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1567205018666211208141017","article-title":"The Alzheimer's disease amyloid precursor protein and its neuritogenic actions","volume":"18","author":"Luu","year":"2021","journal-title":"Curr. Alzheimer Res."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2022.114578_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JMN:23:1-2:105","article-title":"BACE1: the beta-secretase enzyme in Alzheimer's disease","volume":"23","author":"Vassar","year":"2004","journal-title":"J. Mol. Neurosci."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114578_bib36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114578_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1196\/annals.1332.004","article-title":"BACE1 gene expression and protein degradation","volume":"1035","author":"Zhou","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2022.114578_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2021.102113","article-title":"Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer's disease","volume":"204","author":"Xia","year":"2021","journal-title":"Prog. Neurobiol."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114578_bib39","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/MCB.02185-07","article-title":"Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production","volume":"28","author":"Shimizu","year":"2008","journal-title":"Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114578_bib40","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1021\/acs.jmedchem.1c00489","article-title":"Discovery and early clinical development of LY3202626, a low-dose, CNS-penetrant BACE inhibitor","volume":"64","author":"McKinzie","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/ADR-210037","article-title":"Robust pharmacodynamic effect of LY3202626, a central nervous system penetrant, low dose BACE1 inhibitor, in humans and nonclinical species","volume":"6","author":"Willis","year":"2022","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/ADR-210296","article-title":"Phase II (NAVIGATE-AD study) results of LY3202626 effects on patients with mild Alzheimer's disease dementia","volume":"5","author":"Ac Evans","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"issue":"15","key":"10.1016\/j.ejmech.2022.114578_bib43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of Verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ejmech.2022.114578_bib44","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1021\/acs.jmedchem.1c01300","article-title":"Discovery of Umibecestat (CNP520): a potent, selective, and efficacious \u03b2-secretase (BACE1) inhibitor for the prevention of Alzheimer's disease","volume":"64","author":"Machauer","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114578_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of Atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114578_bib46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of Atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114578_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","article-title":"The case for low-level BACE1 inhibition for the prevention of Alzheimer disease","volume":"17","author":"McDade","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib48","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800026","article-title":"BACE2 distribution in major brain cell types and identification of novel substrates","volume":"1","author":"Voytyuk","year":"2018","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.ejmech.2022.114578_bib49","article-title":"BACE1: more than just a \u03b2-secretase","volume":"4","author":"Taylor","year":"2022","journal-title":"Obes. Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114578_bib50","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2174\/1389450121999201230203709","article-title":"Insight \u03b3-secretase: structure, function, and role in Alzheimer's disease","volume":"22","author":"Mal","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2022.114578_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01518-6","article-title":"A\u03b2 profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset","author":"Petit","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114578_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114169","article-title":"Small molecules targeting \u03b3-secretase and their potential biological applications","volume":"232","author":"Wen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14737175.2016.1194203","article-title":"Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies","volume":"17","author":"Amanatkar","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114578_bib54","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with Avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.celrep.2017.09.032","article-title":"Semagacestat is a pseudo-inhibitor of \u03b3-secretase","volume":"21","author":"Tagami","year":"2017","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","article-title":"Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs","volume":"184","author":"Yang","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.cell.2016.08.015","article-title":"Allosteric modulation as a unifying mechanism for receptor function and regulation","volume":"166","author":"Changeux","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114578_bib58","article-title":"\u03b3-Secretase in Alzheimer's disease","volume":"8","author":"Hur","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114578_bib59","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1212\/NXI.0000000000001152","article-title":"Baseline microglial activation correlates with brain Amyloidosis and longitudinal cognitive decline in Alzheimer disease","volume":"9","author":"Wang","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.ejmech.2022.114578_bib60","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/13892037113149990144","article-title":"CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study","volume":"10","author":"Ross","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2022.114578_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1326-7-61","article-title":"Modulation of \u03b3-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice","volume":"7","author":"Rogers","year":"2012","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13578-021-00738-7","article-title":"Turning the tide on Alzheimer's disease: modulation of \u03b3-secretase","volume":"12","author":"Luo","year":"2022","journal-title":"Cell Biosci."},{"issue":"6555","key":"10.1016\/j.ejmech.2022.114578_bib63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.abi6401","article-title":"Treatments for Alzheimer's disease emerge","volume":"373","author":"Selkoe","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114578_bib65","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"Dominantly Inherited Alzheimer Network\u2013Trials Unit. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114578_bib66","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/cpt.2535","article-title":"Disease modeling and model-based meta-Analyses to define a new direction for a phase III program of 64. Gantenerumab in Alzheimer's disease","volume":"111","author":"Retout","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114578_bib67","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of Crenezumab in patients with mild-to-moderate Alzheimer's disease treated with escalating doses for up to 133 weeks","volume":"76","author":"Guthrie","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer's disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2016","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114578_bib70","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain","volume":"32","author":"Hey","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2022.114578_bib71","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fneur.2020.00614","article-title":"A review on tramiprosate (homotaurine) in Alzheimer's disease and other neurocognitive disorders","volume":"11","author":"Manzano","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbadis.2017.07.005","article-title":"A\u03b2 truncated species: implications for brain clearance mechanisms and amyloid plaque deposition","volume":"1864","author":"Cabrera","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114578_bib73","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14728222.2019.1702972","article-title":"Emerging roles of N- and C-terminally truncated A\u03b2 species in Alzheimer's disease","volume":"23","author":"Wirths","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib74","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.107.103242","article-title":"Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats","volume":"51","author":"Padia","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ejmech.2022.114578_bib75","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib76","first-page":"721","article-title":"Targeting brain aminopeptidase A: a new strategy for the treatment of hypertension and heart failure","volume":"36","author":"Marc","year":"2020","journal-title":"Can. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib77","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1471-4159.2009.05950.x","article-title":"Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide","volume":"109","author":"Sevalle","year":"2009","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114578_bib78","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00401-021-02308-0","article-title":"Aminopeptidase A contributes to biochemical, anatomical and cognitive defects in Alzheimer's disease (AD) mouse model and is increased at early stage in sporadic AD brain","volume":"141","author":"Valverde","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114578_bib80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40262-013-0125-y","article-title":"Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug","volume":"53","author":"Balavoine","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","article-title":"A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site","volume":"434","author":"Nabeno","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114578_bib82","article-title":"Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100963","article-title":"Dipeptidyl peptidase 4 contributes to Alzheimer's disease-like defects in a mouse model and is increased in sporadic Alzheimer's disease brains","volume":"297","author":"Valverde","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114578_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4331\/wjbc.v12.i6.104","article-title":"Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer's disease","volume":"12","author":"Ikeda","year":"2021","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114578_bib85","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib86","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.ejmech.2022.114578_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104342","article-title":"Human glutaminyl cyclase: structure, function, inhibitors and involvement in Alzheimer's disease","volume":"147","author":"Vijayan","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114578_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105770","article-title":"Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice","volume":"75","author":"Wang","year":"2019","journal-title":"Int. Immunopharm."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13195-021-00882-9","article-title":"Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD","volume":"13","author":"Vijverberg","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"issue":"21","key":"10.1016\/j.ejmech.2022.114578_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111791","article-title":"Combination of the glutaminyl cyclase inhibitor PQ912 (varoglutamstat) and the murine monoclonal antibody PBD-C06 (m6) shows additive effects on brain A\u03b2 pathology in transgenic mice","volume":"22","author":"Hoffmann","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00401-013-1129-2","article-title":"N-truncated amyloid \u03b2 (A\u03b2) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits","volume":"126","author":"Bouter","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejmech.2022.114578_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.710579","article-title":"N-truncated A\u03b2 starting at position four-biochemical features, preclinical models, and potential as drug target in Alzheimer's disease","volume":"13","author":"Bayer","year":"2021","journal-title":"Front. Aging Neurosci."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114578_bib93","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.3390\/ijms22105191","article-title":"Characterization of a mouse model of Alzheimer's disease expressing A\u03b24-42 and human mutant tau","volume":"22","author":"Zampar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib94","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbadis.2017.07.005","article-title":"A\u03b2 truncated species: implications for brain clearance mechanisms and amyloid plaque deposition","volume":"1864","author":"Cabrera","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2022.114578_bib95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0074-7696(04)35004-7","article-title":"Cell-surface peptidases","volume":"235","author":"Mentlein","year":"2004","journal-title":"Int. Rev. Cytol."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114578_bib96","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0196-9781(95)00021-B","article-title":"Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism","volume":"16","author":"Howell","year":"1995","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2022.114578_bib97","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib98","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/biomedicines9050524","article-title":"Neuroinflammation in Alzheimer's disease","volume":"9","author":"Onyango","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13073-022-01022-0","article-title":"PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease","volume":"14","author":"Tsai","year":"2022","journal-title":"Genome Med."},{"issue":"30","key":"10.1016\/j.ejmech.2022.114578_bib100","doi-asserted-by":"crossref","first-page":"10201","DOI":"10.1523\/JNEUROSCI.1496-12.2012","article-title":"Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology","volume":"32","author":"Bachstetter","year":"2012","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114578_bib101","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpdd.795","article-title":"First-in-Human studies of MW01-6-189WH, a brain-penetrant, Antineuroinflammatory small-molecule drug candidate: phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic studies in healthy Adult volunteers","volume":"10","author":"Van Eldik","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114578_bib102","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1542\/neo.21-3-e165","article-title":"Milrinone use in persistent pulmonary hypertension of the newborn","volume":"21","author":"Qasim","year":"2020","journal-title":"NeoReviews"},{"key":"10.1016\/j.ejmech.2022.114578_bib103","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/NDT.S312648","article-title":"Milrinone ameliorates the neuroinflammation and memory function of Alzheimer's disease in an APP\/PS1 mouse model","volume":"17","author":"Chen","year":"2021","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114578_bib104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-021-00795-7","article-title":"A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2022.114578_bib106","article-title":"Modifying the diet and gut microbiota to prevent and manage neurodegenerative diseases","volume":"21","author":"Gates","year":"2022","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114578_bib107","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fnins.2019.00862","article-title":"Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases","volume":"13","author":"Ryskamp","year":"2019","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib108","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2021.1939681","article-title":"The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer's","volume":"25","author":"Prasanth","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2022.114578_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2022.136528","article-title":"Activation of the sigma-1 receptor attenuates blood-brain barrier disruption by inhibiting amyloid deposition in Alzheimer's disease mice","volume":"774","author":"An","year":"2022","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2022.114578_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108342","article-title":"Sigma ligands as potent inhibitors of A\u03b2 and A\u03b2Os in neurons and promising therapeutic agents of Alzheimer's disease","volume":"190","author":"Ma","year":"2021","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.ejmech.2022.114578_bib111","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer's disease","volume":"12","author":"Rishton","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114578_bib112","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejmech.2022.114578_bib113","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/ADR-200191","article-title":"Phosphodiesterase inhibitors for Alzheimer's disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale","volume":"4","author":"Sanders","year":"2020","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.ejmech.2022.114578_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113818","article-title":"Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease","volume":"176","author":"Zuccarello","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib116","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/bph.15342","article-title":"NO-mediated signal transmission in bladder vasculature as a therapeutic target of PDE5 inhibitors. Rodent model studies","volume":"178","author":"Tanaka","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-018-0352-4","article-title":"Amyloid \u03b2-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition","volume":"10","author":"Bartolome","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114578_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2022.130135","article-title":"Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5\/p25 complex contribute to tau hyperphosphorylation","volume":"1866","author":"Tanaka","year":"2022","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2022.114578_bib119","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.omtn.2021.11.019","article-title":"Implications of miR-148a-3p\/p35\/PTEN signaling in tau hyperphosphorylation and autoregulatory feedforward of Akt\/CREB in Alzheimer's disease","volume":"27","author":"Zeng","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3 Suppl","key":"10.1016\/j.ejmech.2022.114578_bib120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JAD-2006-9S335","article-title":"GSK-3 is essential in the pathogenesis of Alzheimer's disease","volume":"9","author":"Takashima","year":"2006","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.ejmech.2022.114578_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer's disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2022.114578_bib122","first-page":"awab281","article-title":"Astrocyte-neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade","volume":"24","author":"Paumier","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2022.114578_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105026","article-title":"Therapeutic potential of pharmacological agents targeting TRP channels in CNS disorders","volume":"159","author":"Thapak","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114578_bib124","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1744-8069-4-48","article-title":"HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity","volume":"4","author":"Eid","year":"2008","journal-title":"Mol. Pain"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114578_bib125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41573-021-00268-4","article-title":"Advances in TRP channel drug discovery: from target validation to clinical studies","volume":"21","author":"Koivisto","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114578_bib126","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3233\/JAD-210736","article-title":"The FDA Approves Aducanumab for Alzheimer's disease, raising important scientific Questions1","volume":"82","author":"de la Torre","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"Pt 4","key":"10.1016\/j.ejmech.2022.114578_bib127","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/aww017","article-title":"Clinical IMABio3 team. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging","volume":"139","author":"Hamelin","year":"2016","journal-title":"Brain"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:43:48Z","timestamp":1759329828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":127,"alternative-id":["S0223523422004809"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114578","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114578"}}